SEC Filing Summary for Can-Fite BioPharma Ltd.

This filing details a Form 4 filed by Motti Farbstein, CEO, CFO, and COO of Can-Fite BioPharma Ltd. On June 4, 2026, Farbstein acquired 24,000 options to purchase ordinary shares with an exercise price of $2.043 per share. These options will vest in sixteen equal quarterly installments starting September 4, 2026, and ending April 6, 2030, contingent upon continued service. The options were granted under the company's share option plans. Footnote 1 clarifies that these securities must be registered in a trustee's name to qualify for tax benefits under Section 102 of the Israeli Tax Ordinance. Footnote 3 explains that the exercise price, originally in New Israeli Shekels, is presented in USD based on the exchange rate of NIS 2.908 to USD 1.00 as of June 5, 2026.